Skip to main content

Evidence-Based Supplement Research

Evidence-Based Supplement Research

saccharomyces boulardii and Reduced Hospitalization Duration

Doses used in studies

mg/day: 500 (median 500, IQR 500–500) — 1 study

Time to effect

Median: 5 days · IQR 5 days–5 days · Range 5 days–5 days — Reported in 1 of 2 studies

Safety in these studies

Overall tolerabilityReported
None of the trials evaluated the effect of S boulardii on stool volume.
from: Systematic review with meta-analysis: Saccharomyces boulardii for treating acute gastroent
Overall tolerabilityReported
There was no report of any adverse events.
from: Efficacy and Safety of Saccharomyces boulardii in Acute Rotavirus Diarrhea: Double Blind R

2 of 2 papers

Systematic review with meta-analysis: Saccharomyces boulardii for treating acute gastroenteritis in children-a 2020 update.
- 2020-02-13
- Meta-Analysis · n = 3,450
- Alimentary pharmacology & therapeutics 51(7)
- - Hania Szajewska
  - Maciej Kołodziej
  - Bartłomiej M Zalewski
- PubMed: 32056266
- DOI: 10.1111/apt.15659
2 Insights on
- Reduced Hospitalization Duration
- High evidence
- Rigorous Journal
- Clinical
S boulardii use was also associated with a reduced duration of hospitalisation (8 RCTs, n = 999, mean difference -0.85 day, 95% CI -1.35 to -0.34; I2 = 91%) (very low quality of evidence).
Effect
Beneficial
Effect size
Moderate
Significant
Yes
Efficacy and Safety of Saccharomyces boulardii in Acute Rotavirus Diarrhea: Double Blind Randomized Controlled Trial from a Developing Country.
- 2016-06-09
- RCT · n = 60
- Journal of tropical pediatrics 62(6)
- - Susrut Das
  - Pradeep Kumar Gupta
  - Rashmi Ranjan Das
- PubMed: 27283364
- DOI: 10.1093/tropej/fmw032
5 Insights on
- Reduced Hospitalization Duration
- High evidence
- Clinical
A significantly shorter duration of hospitalization (74 vs. 91; 95% CI: -33.46 to -0.54) was also seen in the intervention group
Effect
Beneficial
Effect size
Moderate
Significant
Yes
Dose
500 mg/day for 5 days